toukokuuta 2025 Alun perin tyypin 2 diabeteksen hoitoon kehitetyt GLP-1-lkkeet (glukagonin kaltaisen peptidi-1:n agonistit) jljittelevt elimistn luonnollisen GLP-1-hormonin toimintaa, mutta niiden vaikutus on suunniteltu voimakkaammaksi ja pitkkestoisemmaksi. Tm hormoni stelee ruokahalua, verensokeritasoa ja kyllisyyden tunnetta1
How are GLP-1 drugs changing what people eat
Solutions required (see Box on next page for more details about solution preparation) A
Despite these challenges, biologics offer unprecedented opportunities for advancing cardiovascular treatment
Given that YAP is a transcriptional co-activator known to translocate into the nucleus in response to ECM stiffening in various cell types, including melanoma cells (Miskolczi et al, 2018), and that YAP may serve as a potential MITF partner in uveal melanoma cells (Barbosa et al, 2023), we wondered whether YAP could be associated with the observed ECM-dependent MC phenotypes
While Zepbound itself is not yet directly linked to this condition, its role in managing diabetes may impact the risk
